Navigation Links
Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference
Date:1/8/2009

SAN FRANCISCO, Jan. 8 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the 27th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, at 10:00 a.m. Pacific Time at the Westin St. Francis Hotel in San Francisco.

Dr. Hung will provide an overview of Medivation and its clinical development programs for Dimebon for Alzheimer's and Huntington's diseases and MDV3100 for prostate cancer.

A live audio webcast will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at http://www.medivation.com. A replay also will be available for 30 days following the live presentation.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation entered into a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. With Pfizer, the Company is conducting a broad Dimebon clinical development program, including a pivotal and confirmatory Phase 3 trial, known as the CONNECTION study, in patients with mild-to-moderate Alzheimer's disease. The program also includes additional trials planned to begin this year in Alzheimer's disease, as well as further development of Dimebon in patients with mild-to-moderate Huntington's disease. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Medivation to Announce Early Positive Data from Phase 1-2 Hormone Refractory Prostate Cancer Trial and Host Conference Call and Webcast on Monday, November 5, 2007
2. Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimers Disease in Second Quarter of 2008
3. Medivation to Present at Cowen and Companys 28th Annual Health Care Conference
4. Medivation Announces Participation in Upcoming Conferences
5. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
6. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
7. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
8. HEI, Inc. Announces Sale of RFID Division Assets
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
10. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
11. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2014)... Scientists from The University of Manchester have identified a ... them more open to treatment. , The study published ... way for the development of drugs to target cells ... team made the discovery whilst exploring the possible mechanisms ... to treat breast and colon cancer. , Dr Andrew ...
(Date:4/24/2014)... April 24, 2014 ,Take me out to ... slices and kale chips. The more likely culprits include ... , Unfortunately for children who play youth baseball, ... contributing to weight problems, according to researchers at Wake ... current online edition of Childhood Obesity , found ...
(Date:4/24/2014)... corresponding terminology, and the relevance of palliation in ... on randomized controlled trials (RCTs). This is the ... for Quality and Efficiency in Health Care (IQWiG), ... , Together with external experts, IQWiG analysed studies ... cancer, malignant melanoma, and pancreatic cancer. For this ...
(Date:4/24/2014)... awarded one of 30 grants from the National Cancer ... Site in its new National Clinical Trials Network ... of investigators charged with distributing resources in a more ... system reflects recommendations from a 2010 Institute of ... goals:, Faster design, launch, and completion of ...
(Date:4/23/2014)... by Massachusetts General Hospital (MGH) investigators may lead to ... a serious medical problem use of fecal material ... the Clostridium difficile ( C. difficile ) ... the journal Clinical Infectious Diseases , the researchers ... donors unrelated to patients was as successful in curing ...
Breaking Medicine News(10 mins):Health News:Scientists find way to target cells resistant to chemo 2Health News:Take the bat, leave the candy 2Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3
... theory that contemporary orgasms succor fertility found that women who ... than those that did not. The best way to get ... scientists have ascertained. ,Dr Cathy, from the School of ... age of 32. //The women were asked to go to ...
... sexual intercorse soon after delivery could jeopardize their lives. A ... occured because they indulged in sexual intercourse too soon after ... air embolisms, traveling to the heart and brain.The blood vessels ... upto 4 weeks to return to normal after birth. The ...
... females who are given a choice to select their partners ... research involves the humble fruit fly, but experts believe it ... from the University of Georgia, led by Dr Daniel Promislow, ... in a vial with one virgin female.// Some of the ...
... AIDS will surpass the Black Death as the world's worst ... AIDS do not get life prolonging drugs. The illness has ... 14,000 people are infected each day with HIV, which destroys ... living with AIDS will die, pushing the death toll beyond ...
... out a high number of operations have lower deaths rates ... a scientist at the Institute of Public Health in Cambridge, ... 12 hospitals carrying// out heart surgery on children from 1991 ... carrying out 120 open heart operations on children less than ...
... of countries where leprosy is still a health problem need ... curable disease, the World Health Organization (WHO) has said. Partners ... meeting in Brazil for their annual meeting. Brazil is one ... major public health issue. The others are India, Madagascar, Mozambique, ...
Cached Medicine News:
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
(Date:1/15/2014)... Mass. , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ...
(Date:1/14/2014)... , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... for the fourth quarter of 2013 on Monday, February 3, ... release after the close of trading. (Logo: ... call to discuss the operating highlights and financial results for ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... 18 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA),a leading developer ... it,will hold its 2010 Annual Meeting of Shareholders on Thursday, ... meeting will be held concurrently at No. 39,Shangdi Xi Road, Haidian ... St.,John,s, Antigua . All shareholders of record as of ...
... WASHINGTON , June 17 The chairman of ... the U.S. Food and Drug Administration (FDA) over its move toward ... "emergency contraceptive." In a June 17 letter to Dr. ... DiNardo of Galveston - Houston criticized the FDA,s ...
Cached Medicine Technology:Sinovac Schedules 2010 Annual Meeting of Shareholders 2Sinovac Schedules 2010 Annual Meeting of Shareholders 3Pro-Life Chair Voices 'Grave Concern' over FDA Plan to Approve Abortion Drug for 'Emergency Contraception' 2Pro-Life Chair Voices 'Grave Concern' over FDA Plan to Approve Abortion Drug for 'Emergency Contraception' 3Pro-Life Chair Voices 'Grave Concern' over FDA Plan to Approve Abortion Drug for 'Emergency Contraception' 4
... a biocompatible, flexible, one-piece artificial cornea (keratoprosthesis) ... native cornea., ,The World Health Organisation (WHO) ... 10 million people worldwide, however only 100,000 ... shortfall is due to a combination of ...
PDA application providing complex evaluation and management coding rule interactive templates....
Provides access via PDA to determine whether imaging examinations are necessary based on symptons and which studies will generate the most information....
PDA-version of the leading portable drug reference....
Medicine Products: